The 20/2/20 Rule in High-Risk Smoldering Myeloma
The 20/2/20 rule (also called Mayo 2018 criteria) is a risk stratification system for smoldering multiple myeloma that identifies high-risk patients based on three factors: bone marrow plasma cells >20%, M-protein >2 g/dL, and free light chain ratio >20, with patients having ≥2 of these factors classified as high-risk. 1
Definition and Components
The Mayo 2018 20/2/20 criteria stratify smoldering myeloma patients using three independent risk factors 1:
- Bone marrow plasma cell infiltration >20% (hazard ratio 2.4) 2
- Serum M-protein >2 g/dL (hazard ratio 2.1) 2
- Free light chain ratio >20 (involved to uninvolved; hazard ratio 2.7) 2
Risk Categories and Progression Rates
The NCCN guidelines recommend using this system to categorize patients into three distinct risk groups 1:
- Low risk (0 factors): 6% progression at 2 years, median time to progression 110 months 1, 2
- Intermediate risk (1 factor): 18% progression at 2 years, median time to progression 68 months 1, 2
- High risk (≥2 factors): 44% progression at 2 years, median time to progression 29 months 1, 2
This model was validated in a large retrospective analysis of 2,004 patients, confirming estimated progression rates at 2 years of 5%, 17%, and 46% for low-, intermediate-, and high-risk disease respectively 1.
Clinical Application and Management
For high-risk patients (≥2 factors), the NCCN Panel recommends enrollment in clinical trials as preferred, or treatment with single-agent lenalidomide in carefully selected patients (category 2B), or close observation at 3-month intervals. 1 The EHA-EMN guidelines now support daratumumab monotherapy for 3 years in high-risk SMM patients, though regulatory approval was pending at the time of their 2025 publication 3.
For low-risk patients, observation at 3- to 6-month intervals is recommended (category 1) 1.
Important Clinical Considerations
A critical caveat: approximately 45% of high-risk SMM patients who progress on active surveillance develop clinically significant end-organ damage (hypercalcemia, renal insufficiency, and/or bone lesions) at the time of progression. 4 Additionally, about 25% of patients who progress are not diagnosed based on routine surveillance testing alone, highlighting the need for vigilant monitoring 4.
The 20/2/20 criteria were developed from a retrospective study of 417 patients and represent an improvement over earlier models by incorporating readily available laboratory parameters that don't require specialized flow cytometry 1. This makes the system widely applicable in routine clinical practice 2.
Enhanced Risk Stratification
When cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) are added to the 20/2/20 model, four risk groups can be identified with 2-year progression risks of 6%, 23%, 46%, and 63% for patients with 0,1,2, or ≥3 risk factors respectively 2. However, the NCCN guidelines primarily recommend the three-factor model for standard practice 1.